MARC Record from Library of Congress

LEADER: 02719cam a22003734a 4500
001 2011015645
003 DLC
005 20120302174705.0
008 110412s2011 nyua b 001 0 eng
010 $a 2011015645
016 7 $a015826452$2Uk
020 $a9781613246399 (hardcover : alk. paper)
020 $a1613246390 (hardcover : alk. paper)
035 $a(OCoLC)ocn713186259
040 $aDNLM/DLC$cDLC$dYDX$dBTCTA$dYDXCP$dUKMGB$dDLC
042 $apcc
050 00 $aRS100$b.P73 2011
060 10 $aQV 736
082 00 $a615/.1$223
245 00 $aPrescription drug pricing :$bcost and control concerns /$cJonathan R. Dickson and Amy M. Woebler, editors.
260 $aNew York :$bNova Science Publishers,$cc2011.
300 $aviii, 139 p. :$bill. ;$c24 cm.
490 0 $aHealth care issues, costs and access
490 0 $aDrug transit and distribution, interception and control
504 $aIncludes bibliographical references and index.
505 0 $aPrescription drugs : trends in usual and customary prices for commonly used drugs / GAO -- Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases / GAO -- Overview of approaches to control prescription drug spending in federal programs / Statement of John E. Dicken, Director, Health Care, (GAO) -- Opening statement of U.S. Senator Amy Klobuchar, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry" / statement of Senator Charles E. Schumer, Chairman, Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry" -- Statement of Madeline M. Carpinelli, Stephen W. Schondelmeyer, Prime Institute, College of Pharmacy, University of Minnesota, before the Joint Economic Committee, hearing on "Extraordinary price increases in the pharmaceutical market" -- Testimony of Alan L. Goldbloom, MD, president and CEO, Children's Hospitals and Clinics of Minnesota, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry" -- Testimony of Danielle Foltz, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry" -- Entry threats and pricing in the generic drug industry / Brett Wendling, Steven Tenn.
650 0 $aPrescription pricing$zUnited States.
650 0 $aMedical economics$zUnited States.
650 2 $aDrug Costs$zUnited States.
650 2 $aPrescription Drugs$xeconomics$zUnited States.
650 2 $aCosts and Cost Analysis$zUnited States.
650 2 $aDrug Industry$xeconomics$zUnited States.
700 1 $aDickson, Jonathan R.
700 1 $aWoebler, Amy M.